Thalidomide and rituximab in Waldenstrom macroglobulinemia

Thalidomide enhances rituximab-mediated, antibody-dependent, cell-mediated cytotoxicity. We therefore conducted a phase 2 study using thalidomide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to either agent. Intended therapy consisted of daily thalidomide (200 mg fo...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Treon, Steven P., Soumerai, Jacob D., Branagan, Andrew R., Hunter, Zachary R., Patterson, Christopher J., Ioakimidis, Leukothea, Briccetti, Frederick M., Pasmantier, Mark, Zimbler, Harvey, Cooper, Robert B., Moore, Maria, Hill, John, Rauch, Alan, Garbo, Lawrence, Chu, Luis, Chua, Cynthia, Nantel, Stephen H., Lovett, David R., Boedeker, Hans, Sonneborn, Henry, Howard, John, Musto, Paul, Ciccarelli, Bryan T., Hatjiharissi, Evdoxia, Anderson, Kenneth C.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Hematology 2008
Θέματα:
Clinical Trials and Observations
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2597120/
https://ncbi.nlm.nih.gov/pubmed/18713945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-04-150854
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια